SecBot SecBot

QTTB drug pipeline

Q32 Bio Inc. · 1 rated drug
$8.29
−4.8% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 mixed
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 2
Time to marketAt least 3-5 years. Registration-directed (Phase 3) program expected to begin in H1 2027; typical Phase 3 + FDA review takes 3-4 years from initiation.

bempikibart Updated Jul 13

What to watch

The July 13 positive Phase 2a data has already been priced in (~60% single-day surge). The next meaningful catalyst is the start of a Phase 3 registration program in H1 2027, but that is a process milestone, not a binary event. Investors should watch for FDA feedback on the registration-directed plan, potential partnership interest given the clean safety profile, and additional financing rounds as Q32 Bio will need capital to fund the pivotal trials.

Bull case
  • First-in-class anti-IL-7Rα mechanism differentiates bempikibart from approved JAK inhibitors (Olumiant, Litfulo), all of which carry FDA black-box warnings for infections, cardiovascular events, and malignancy, bempikibart showed no Grade 3+ adverse events in the SIGNAL-AA trial, suggesting a potentially superior safety profile.
  • Positive Phase 2a Part B data (35.3% mean SALT reduction, 40% SALT-20 response at Week 36) with durable effects persisting after treatment cessation supports disease-modifying potential, with investors already rewarding with a ~60% single-day surge on July 13, 2026.
  • FDA Fast Track designation (April 2025) for AA provides accelerated regulatory pathway with more frequent FDA engagement, potentially compressing development timelines.
Bear case
  • The SIGNAL-AD (atopic dermatitis) Phase 2a trial failed its primary endpoint in December 2024, raising questions about bempikibart's broader autoimmune potential and whether the mechanism works across indications.
  • Part B of SIGNAL-AA was an open-label, single-arm study with only 25 evaluable patients in the mITT population, a small sample size that limits statistical robustness; results may not replicate in larger, blinded, placebo-controlled Phase 3 trials.
  • Competing JAK inhibitors (Pfizer's Litfulo, Lilly's Olumiant) are already approved for AA with established commercial infrastructure and multi-hundred-million-dollar revenue, bempikibart would need to overcome their market presence.

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
bempikibartA Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)Phase 2Active not recruiting75Jun 2026